&w=3840&q=100)
Breakthrough in hunt for AIDS treatment: Scientists develop new mRNA technique for permanent HIV treatment
Scientists have seemed to have found a breakthrough in curing the deadly HIV AIDS, which will force the virus out of blood cells.
The possible cure tackles the HIV's ability to conceal itself in white blood cells, capable of reactivation, rendering any treatment or drug useless to deal with the virus.
A paper published in Nature Communications says that scientists at the Peter Doherty Institute for Infection and Immunity in Melbourne have tapped into mRNA technology to locate the AIDS virus and thereby fully clear it from an infected body.
STORY CONTINUES BELOW THIS AD
For the first time, researchers have demonstrated that mRNA can be delivered into the cells harbouring hidden HIV by encasing it in a specially designed microscopic fat bubble. Once inside, the mRNA prompts the cells to expose the dormant virus.
Dr Paula Cevaal, the co-author of the study, said the employment of mRNA technology in the type of white blood cell that is home to HIV was earlier thought to be 'impossible' as those cells did not take up the fat bubbles, or lipid nanoparticles (LNPs) that are used to carry them.
Our hope is that this new nanoparticle design could be a new pathway to an HIV cure,' Cevaal said, adding that her team has developed a new type of LNP that those cells will accept, known as LNP X.
However, more research is required to determine whether merely exposing the virus is sufficient for the immune system to eliminate it, or if this approach needs to be paired with other treatments to fully eradicate HIV from the body.
'In the field of biomedicine, many things eventually don't make it into the clinic – that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality. But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus,' Cevaal said.
STORY CONTINUES BELOW THIS AD
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
14 minutes ago
- Hindustan Times
Skin awareness camps held across India in world records attempt
The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) organised skin health awareness camps at multiple locations across the country, including 28 camps in Delhi, on Sunday as part of an International Book of Records attempt for the largest number of free Skin Health Camps and Public Awareness Programmes conducted on a single day. The health camp at a school in Jangpura, New Delhi on Sunday. (Vipin Kumar/HT Photo) The camps were part of IADVL's campaign themed 'No Health Without Skin Health,' which aimed to raise awareness about the importance of skin health in achieving overall physical, mental, and social well-being, according to the president of the association, Dr Deepika Pandhi. At the Sarvodaya Kanya Vidyalaya in Pushp Vihar, where one of the Delhi camps was held, children accompanied by their guardians began arriving as early as 10am to seek free consultations and advice. Manish Kumar, 36, who brought his daughter to the camp, said, 'My 14-year-old daughter has been struggling with acne issues for a while that often affect her confidence. I had tried over-the-counter skin creams. Today at the camp, after the consultation, I found out how her diet could also have a huge role, and now we are going to work on that.' Another parent, Sona Mukherjee, 38, said, 'My daughter informed me that their school was going to have a skin health camp, and I thought maybe I should come to get myself checked, and I'm glad I did. I was having skin rashes for a long time but was just avoiding going to a doctor. Now, from the camp, I've been asked to get a few tests done and have been prescribed some medication.' Visitors said the camp helped them challenge misconceptions. 'I used to think that vitiligo can spread by touching, but after today's camp, that myth has been debunked for me,' Sona added. Speaking at the Pushp Vihar camp, Dr Pandhi said that a lot of their patients were young people. 'The aim was to educate them that topical steroid creams are prescription medicines not cosmetic or fairness products and their misuse can cause serious side effects. These include skin thinning, stretch marks, acne, pigment changes, delayed wound healing, and worsening of fungal infections like ringworm, which has reached epidemic proportions largely due to steroid misuse.' She also stressed that the foundation of healthy skin lies in balanced nutrition, regular exercise, and proper skincare, and urged the public to avoid self-medication and unregulated cosmetic practices. The camps across Delhi were held at schools, old-age homes, medical colleges, schools for the visually impaired, and orphanages. More than 35 dermatologists from IADVL Delhi State Branch participated, offering free consultations, the association said. The campaign also sought to highlight that HIV/AIDS is a manageable chronic illness. With adherence to antiretroviral therapy, nutritious diets, and medical supervision, people with HIV can lead long, healthy, and productive lives. 'AIDS is not a death sentence; it is a chronic manageable disease,' Dr Pandhi added.
The Print
13 hours ago
- The Print
UNAIDS 2025 report warns of funding gaps in fight against HIV as India battles stigma, discrimination
Also, in India, more than 80 percent of surveyed women aged between 15 and 49 years were reported between 2020 and 2024 to lack autonomy over their sexual choices and reproductive healthcare. Additionally, over 90 percent of them lacked information about contraceptive use. The report titled 'AIDS, Crisis And The Power To Transform', released on 10 July, also highlights that the prevalence of intimate partner violence among partnered or married women living with HIV in the same age group in India stood at 24 percent—just 10 percent less than Liberia, where the prevalence was found to be highest globally. The figures are based on data from 2020-2024. New Delhi: The 2025 Global AIDS Update by UNAIDS (Joint United Nations Programme on HIV/AIDS) shows that 30 percent of people surveyed in the 15-49 age group in India reported facing HIV-related stigma and discrimination. The 2025 update notes the impact that massive funding cuts by international donors are having on countries most affected by HIV, and how the threat of a funding crisis may hurt global progress in the fight against HIV/AIDS unless countries alter their programming. According to the UNAIDS Executive Director Winnie Byanyima, the Global HIV response shows a decline of newly HIV infected persons by 40 percent, and of 56 percent deaths since 2010. However, the withdrawal of the US President's Emergency Plan for AIDS Relief (PEPFAR), the biggest contributor to global response, may lead to 6 million additional people being infected, and an additional 4 million deaths by 2029. The funding crisis has disrupted treatment and prevention programmes around the world, the report says. But it also points to the emergence of new prevention tools, like Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP), 'which has shown near-complete efficacy in clinical trials'. It can prevent HIV with injection doses twice a year. The manufacturer of Lenacapavir, Gilead Sciences, has licenced six generic manufacturers, of which Dr Reddy's Laboratories, Emcure, Hetero, and Mylan—subsidiary of Viatris—operate in India. However, affordability and access are still big challenges. According to the report, in terms of region-wise distribution, Eastern and Southern Africa saw the highest new HIV infections in 2024 at 37 percent, the lowest being in the Caribbean at one percent. In Asia and the Asia Pacific, of which India is a part, the figure stands at 23 percent. With respect to people living with HIV in 2024, the highest was reported in Eastern and Southern Africa at 52 percent, or 21.1 million. The lowest number of people was in the Caribbean—one percent, or 3,40,000. In Asia and Asia Pacific, the number was 17 percent, or 6.9 million. India is among the 13 of the 35 reporting countries that have reached safe injecting targets—90 percent using sterile equipment at last injection. It is clubbed with South Africa, Thailand and Brazil under Low-Dependency Countries in the matrix of dependency on PEPFAR funding. The report also mentions that social enterprises help diversify revenue resources. In India, the Mist LGBTQ Foundation runs an online platform to market merchandise, and offer HIV self-testing and PrEP consultations, either free or at a low rate. Another organisation, the Network of Maharashtra People Living with HIV TAAL+ Pharmacy sells antiretroviral and other medicines at discounted prices via corporate social responsibility partnerships. (Edited by Mannat Chugh) Also Read: Bringing dramatic drop in TB deaths, how TN set an example for rest of India with one-of-a-kind model
Time of India
20 hours ago
- Time of India
US aid cuts halt HIV vaccine research in South Africa, with global impact
Johannesburg: Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine , and hopes were high for another step toward limiting one of history's deadliest pandemics. Then the email arrived. Stop all work, it said. The United States under the Trump administration was withdrawing all its funding. The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the world. Their research project, called BRILLIANT , was meant to be the latest to draw on the region's genetic diversity and deep expertise in the hope of benefiting people everywhere. But the $46 million from the U.S. for the project was disappearing, part of the dismantling of foreign aid by the world's biggest donor earlier this year as President Donald Trump announced a focus on priorities at home. South Africa hit hard by aid cuts South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the country's white Afrikaner minority. The country had been receiving about $400 million a year via USAID and the HIV-focused PEPFAR. Now that's gone. Glenda Grey, who heads the Brilliant program, said the African continent has been vital to the development of HIV medication, and the U.S. cuts threaten its capability to do such work in the future. Significant advances have included clinical trials for lenacapavir, the world's only twice-a-year shot to prevent HIV, recently approved for use by the U.S. Food and Drug Administration. One study to show its efficacy involved young South Africans. "We do the trials better, faster and cheaper than anywhere else in the world, and so without South Africa as part of these programs, the world, in my opinion, is much poorer," Gray said. She noted that during the urgency of the COVID-19 pandemic , South Africa played a crucial role by testing the Johnson & Johnson and Novavax vaccines, and South African scientists' genomic surveillance led to the identification of an important variant. Labs empty and thousands are laid off A team of researchers at the University of the Witwatersrand has been part of the unit developing the HIV vaccines for the trials. Inside the Wits laboratory, technician Nozipho Mlotshwa was among the young people in white gowns working on samples, but she may soon be out of a job. Her position is grant-funded. She uses her salary to support her family and fund her studies in a country where youth unemployment hovers around 46%. "It's very sad and devastating, honestly," she said of the U.S. cuts and overall uncertainty. "We'll also miss out collaborating with other scientists across the continent." Professor Abdullah Ely leads the team of researchers. He said the work had promising results indicating that the vaccines were producing an immune response. But now that momentum, he said, has "all kind of had to come to a halt." The BRILLIANT program is scrambling to find money to save the project. The purchase of key equipment has stopped. South Africa's health department says about 100 researchers for that program and others related to HIV have been laid off. Funding for postdoctoral students involved in experiments for the projects is at risk. South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research funding over the next five years due to the aid cuts, which affect not only work on HIV but also tuberculosis - another disease with a high number of cases in the country. Less money, and less data on what's affected South Africa's government has said it will be very difficult to find funding to replace the U.S. support. And now the number of HIV infections will grow. Medication is more difficult to obtain. At least 8,000 health workers in South Africa's HIV program have already been laid off, the government has said. Also gone are the data collectors who tracked patients and their care, as well as HIV counselors who could reach vulnerable patients in rural communities. For researchers, Universities South Africa, an umbrella body, has applied to the national treasury for over $110 million for projects at some of the largest schools. During a visit to South Africa in June, UNAIDS executive director Winnie Byanyima was well aware of the stakes, and the lives at risk, as research and health care struggle in South Africa and across Africa at large. Other countries that were highly dependent on U.S. funding including Zambia, Nigeria, Burundi and Ivory Coast are already increasing their own resources, she said. "But let's be clear, what they are putting down will not be funding in the same way that the American resources were funding," Byanyima said.
